Allarity Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Allarity Therapeutics, Inc. (Nasdaq: ALLR) on December 23, 2025. The report details an additional closing of a private placement transaction previously initiated on September 22, 2025.
Key Financial Metrics
- Transaction Type: Unregistered sale of equity securities (Additional Closing of Private Placement).
- Shares Issued: 255,103 shares of Common Stock.
- Price Per Share: $0.98 (Minimum Price under Nasdaq Rule 5635(d)).
- Gross Proceeds: Approximately $250,000.
- Use of Proceeds: General corporate purposes and working capital.
- Financial Statements: The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The filing reports the completion of an additional tranche of a private placement. This represents a capital raise event rather than an operational change. The total gross proceeds from the initial September 2025 transaction were approximately $2.5 million; this December 2025 closing adds approximately $250,000 to that total.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future performance, or specific risk factors beyond standard disclosures regarding the unregistered nature of the securities. The securities were sold pursuant to Section 4(a)(2) of the Securities Act of 1933 and are subject to restrictive legends.
Investor Verification Checklist
- Verify the total aggregate proceeds from the full Private Placement (September and December closings combined).
- Confirm the current share count and dilution impact of the 255,103 additional shares issued.
- Review the company's most recent 10-K or 10-Q for updated liquidity and working capital positions.
- Check for any subsequent filings regarding the utilization of the $250,000 in proceeds.